RT Journal Article
SR Electronic
T1 Genomic epidemiology of SARS-CoV-2 in Mauritius reveals a new wave of infections dominated by the B.1.1.318, a variant under investigation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.16.21259017
DO 10.1101/2021.06.16.21259017
A1 Tegally, Houriiyah
A1 Ramuth, Magalutcheemee
A1 Amoaka, Daniel
A1 Scheepers, Cathrine
A1 Wilkinson, Eduan
A1 Giovanetti, Marta
A1 Lessells, Richard J
A1 Giandhari, Jennifer
A1 Ismail, Arshad
A1 Martin, Darren
A1 San, Emmanuel James
A1 Crawford, Margaret
A1 Daniels, Rodney S
A1 Harvey, Ruth
A1 Bahadoor, Somduthsingh
A1 Sonoo, Janaki
A1 Timol, Myriam
A1 Veerapa-Mangroo, Lovena
A1 Gottberg, Anne von
A1 Bhiman, Jinal N.
A1 de Oliveira, Tulio
A1 Manraj, Shyam
YR 2021
UL http://medrxiv.org/content/early/2021/06/16/2021.06.16.21259017.abstract
AB Mauritius, a small island in the Indian Ocean, has had a unique experience of the SARS-CoV-2 pandemic. In March 2020, Mauritius endured a small first wave and quickly implemented control measures which allowed elimination of local transmission of SARS-CoV-2. When borders to the island reopened, it was accompanied by mandatory quarantine and testing of incoming passengers to avoid reintroduction of the virus into the community. As variants of concern (VOCs) emerged elsewhere in the world, Mauritius began using genomic surveillance to keep track of quarantined cases of these variants. In March 2021, another local outbreak occurred, and sequencing was used to investigate this new wave of local infections. Here, we analyze 154 SARS-CoV-2 viral genomes from Mauritius, which represent 12% of all the infections seem in Mauritius, these were both from specimens of incoming passengers before March 2021 and those of cases during the second wave. Our findings indicate that despite the presence of known VOCs Beta (B.1.351) and Alpha (B.1.1.7) among quarantined passengers, the second wave of local SARS-CoV-2 infections in Mauritius was caused by a single introduction and dominant circulation of the B.1.1.318 virus. The B.1.1.318 variant is characterized by fourteen non-synonymous mutations in the S-gene, with five encoded amino acid substitutions (T95I, E484K, D614G, P681H, D796H) and one deletion (Y144del) in the Spike glycoprotein. This variant seems to be increasing in prevalence and it is now present in 34 countries. This study highlights that despite having stopped the introduction of more transmissible VOCs by travel quarantines, a single undetected introduction of a B.1.1.318 lineage virus was enough to initiate a large local outbreak in Mauritius and demonstrated the need for continuous genomic surveillance to fully inform public health decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe generation of data was funded by the Department of Science and Innovation and the South African Medical Research Council (SAMRC). The collection of the samples was funded by the Ministry of Health and Wellness, Port Louis, Mauritius and by the Central Health Laboratory, Victoria Hospital, Candos, Mauritius.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee. Protocol reference number: BREC/00001195/2020. Project title: COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care. The Ethics amendment was approved to expand the analysis of public and anonymized data from Africa.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the genomes are available in GISAID.